- Home
- BCDA vs ILAG Comparison
BCDA vs ILAG Comparison
Compare BCDA & ILAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ILAG
- Stock Information
- Founded
- BCDA N/A
- ILAG 1981
- Country
- BCDA United States
- ILAG Hong Kong
- Employees
- BCDA N/A
- ILAG N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ILAG Office Equipment/Supplies/Services
- Sector
- BCDA Health Care
- ILAG Consumer Discretionary
- Exchange
- BCDA Nasdaq
- ILAG Nasdaq
- Market Cap
- BCDA 11.0M
- ILAG 9.4M
- IPO Year
- BCDA N/A
- ILAG 2022
- Fundamental
- Price
- BCDA $2.15
- ILAG $0.50
- Analyst Decision
- BCDA Strong Buy
- ILAG
- Analyst Count
- BCDA 1
- ILAG 0
- Target Price
- BCDA $25.00
- ILAG N/A
- AVG Volume (30 Days)
- BCDA 52.3K
- ILAG 560.2K
- Earning Date
- BCDA 08-12-2025
- ILAG 07-07-2025
- Dividend Yield
- BCDA N/A
- ILAG N/A
- EPS Growth
- BCDA N/A
- ILAG N/A
- EPS
- BCDA N/A
- ILAG N/A
- Revenue
- BCDA $3,000.00
- ILAG $7,506,551.00
- Revenue This Year
- BCDA N/A
- ILAG N/A
- Revenue Next Year
- BCDA N/A
- ILAG N/A
- P/E Ratio
- BCDA N/A
- ILAG N/A
- Revenue Growth
- BCDA N/A
- ILAG 16.50
- 52 Week Low
- BCDA $1.63
- ILAG $0.34
- 52 Week High
- BCDA $4.66
- ILAG $1.35
- Technical
- Relative Strength Index (RSI)
- BCDA 51.13
- ILAG 51.82
- Support Level
- BCDA $1.98
- ILAG $0.41
- Resistance Level
- BCDA $2.45
- ILAG $0.56
- Average True Range (ATR)
- BCDA 0.17
- ILAG 0.10
- MACD
- BCDA 0.01
- ILAG -0.00
- Stochastic Oscillator
- BCDA 53.19
- ILAG 26.15
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.